-
Enzalutamide (CAS 915087-33-1) is a high-purity androgen receptor inhibitor API, specially designed for targeted treatment of prostate cancer. With a precise molecular structure, it selectively binds to androgen receptors, blocking androgen signaling pathways and effectively inhibiting the proliferation and survival of hormone-dependent prostate cancer cells.
-
Produced under strict GMP standards, this API ensures consistent purity (≥99%), potency, and stability, making it ideal for pharmaceutical formulation. It is widely applied in the development of drugs for castration-resistant prostate cancer (CRPC) and metastatic prostate cancer treatment, catering to the needs of pharmaceutical manufacturers and research institutions focusing on antitumor pharmaceutical R&D.
-
Its specific androgen receptor inhibition mechanism ensures targeted efficacy while reducing systemic toxicity, achieving a favorable balance between therapeutic effect and safety. As a core raw material for prostate cancer targeted therapy, Enzalutamide delivers reliable performance for both preclinical research and large-scale pharmaceutical production, supporting the development of effective treatments for advanced prostate cancer.
Enzalutamide (CAS 915087-33-1) – Androgen Receptor Inhibitor API
$240,000.00
Enzalutamide – Androgen Receptor Inhibitor is an androgenic steroid primarily used for testosterone replacement therapy in males with hypogonadism, as well as for the treatment of delayed puberty and certain types of breast cancer in women.
Be the first to review “Enzalutamide (CAS 915087-33-1) – Androgen Receptor Inhibitor API”
Reviews
There are no reviews yet.